Evidence-based Medicine Newsletter
Extended duration dual antiplatelet therapy was not associated with a difference in the risk of all-cause, cardiovascular, or non-cardiovascular death compared with Aspirin alone
Treatment with Aspirin ( Acetylsalicylic acid ) and a P2Y12 inhibitor is commonly used in patients with cardiovascular disorders. The overall effect of such treatment on all-cause mortality is unknown …
Ambulatory patients with cancer: Heparin may have a small effect on mortality at 12 months and 24 months
Anticoagulation may improve survival in patients with cancer through an antitumor effect in addition to the perceived antithrombotic effect. The purpose of a study was to evaluate the efficacy and …
Cardiovascular risk: effects of blood pressure lowering according to baseline body-mass index
The cardiovascular benefits of blood pressure lowering in obese people compared with people of normal weight might depend on choice of drug. Researchers compared the effects of blood pressure-loweri …
Polypill strategy improves adherence for secondary prevention following an acute myocardial infarction
Adherence to evidence-based cardiovascular medications after an acute myocardial infarction is low after the first 6 months. The use of fixed-dose combinations ( FDC ) has been shown to improve treatm …
Venous thromboembolism: statins for primary prevention
Venous thromboembolism ( VTE ) is common in clinical practice. The efficacy of statins in the primary prevention of VTE remains unproven. This is an update of the review first published in 2011. Th …
Diabetes mellitus: Saxagliptin associated with an increased risk or hospitalization for heart failure
Diabetes mellitus and heart failure frequently coexist. However, few diabetes mellitus trials have prospectively evaluated and adjudicated heart failure as an end point. In the SAVOR-TIMI 53 trial, … –
Per iscriversi alla Newsletter Evidence Medicine in inglese
Coloro che sono GIA’ ISCRITTI ad altre Newsletter Xagena possono accedere al Pannello di Controllo al sito XagenaWeb.it inserendo l’indirizzo e-mail con il quale ricevono le Newsletter e la Password personale [ RIPORTATA IN FONDO A OGNI NEWSLETTER ] E’ importante confermare la modifica cliccando sul tasto SALVA MODIFICA